SELLAS Life Sciences Granted Orphan Drug Designation By European Commission For SLS009, A Novel CDK9 Inhibitor For Treating Acute Myeloid Leukemia
SELLAS Life Sciences Granted Orphan Drug Designation By European Commission For SLS009, A Novel CDK9 Inhibitor For Treating Acute Myeloid Leukemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.